Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2024 Jul 1;159(7):727-735.
doi: 10.1001/jamasurg.2023.5947.

Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis: A Secondary Analysis of the APPAC II Randomized Clinical Trial

Affiliations
Randomized Controlled Trial

Three-Year Outcomes of Oral Antibiotics vs Intravenous and Oral Antibiotics for Uncomplicated Acute Appendicitis: A Secondary Analysis of the APPAC II Randomized Clinical Trial

Liisa Selänne et al. JAMA Surg. .

Abstract

Importance: Current short-term evidence has shown that uncomplicated acute appendicitis can be treated successfully with oral antibiotics alone, but longer-term results are lacking.

Objective: To assess the treatment effectiveness of oral antibiotic monotherapy compared with combined intravenous (IV) and oral antibiotics in computed tomography-confirmed uncomplicated acute appendicitis at a longer-term follow-up.

Design, setting, and participants: This secondary analysis of a predefined year 3 follow-up of the Appendicitis Acuta II (APPAC II) noninferiority, multicenter randomized clinical trial compared oral moxifloxacin with combined IV ertapenem plus oral levofloxacin and metronidazole for the treatment of uncomplicated acute appendicitis. The trial was conducted at 9 university and central hospitals in Finland from April 2017 to November 2018, with the last follow-up in November 2022. Participants included patients aged 18 to 60 years, who were randomized to receive either oral antibiotics monotherapy (n = 301) or combined IV and oral antibiotics (n = 298).

Interventions: Antibiotics monotherapy consisted of oral moxifloxacin, 400 mg/d, for 7 days. Combined IV and oral antibiotics consisted of IV ertapenem sodium, 1 g/d, for 2 days plus oral levofloxacin, 500 mg/d, and metronidazole, 500 mg 3 times/d, for 5 days.

Main outcomes and measures: The primary end point was treatment success, defined as the resolution of acute appendicitis and discharge from hospital without the need for surgical intervention and no appendicitis recurrence at the year 3 follow-up evaluated using a noninferiority design. The secondary end points included late (after 1 year) appendicitis recurrence as well as treatment-related adverse events, quality of life, length of hospital stay, and length of sick leave, which were evaluated using a superiority design.

Results: After exclusions, 599 patients (mean [SD] age, 36 [12] years; 336 males [56.1%]) were randomized; after withdrawal and loss to follow-up, 582 patients (99.8%) were available for the year 3 follow-up. The treatment success at year 3 was 63.4% (1-sided 95% CI, 58.8% to ∞) in the oral antibiotic monotherapy group and 65.2% (1-sided 95% CI, 60.5% to ∞) in the combined IV and oral antibiotics group. The difference in treatment success rate between the groups at year 3 was -1.8 percentage points (1-sided 95% CI, -8.3 percentage points to ∞; P = .14 for noninferiority), with the CI limit exceeding the noninferiority margin. There were no significant differences between groups in treatment-related adverse events, quality of life, length of hospital stay, or length of sick leave.

Conclusions and relevance: This secondary analysis of the APPAC II trial found a slightly higher appendectomy rate in patients who received oral antibiotic monotherapy; however, noninferiority of oral antibiotic monotherapy compared with combined IV and oral antibiotics could not be demonstrated. The results encourage future studies to assess oral antibiotic monotherapy as a viable treatment alternative for uncomplicated acute appendicitis.

Trial registration: ClinicalTrials.gov Identifier: NCT03236961.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Selänne reported receiving a research grant awarded to Turku University Hospital from the Finnish government and personal fees from Turun Yliopistosäätiö (Turku University Foundation) during the conduct of the study. Dr Haijanen reported receiving a research grant awarded to Turku University Hospital from the Finnish government and grants from Orion Research Foundation, Gastroenterological Research Foundation, Paulo Foundation, and Mary and Georg C. Ehrnrooth Foundation during the conduct of the study. Dr Sippola reported receiving grants awarded to Hospital District of Southwest Finland from the Finnish government, grants from the Finnish Medical Foundation, Orion Research Foundation, and Mary and Georg C. Ehrnrooth Foundation during the conduct of the study. Dr Marttila reported receiving grants from Pfizer Travel Grant ECCMID 2023 outside the submitted work. Dr Salminen reported receiving grants from Sigrid Jusélius Foundation and Academy of Finland during the conduct of the study as well as personal fees from Novo Nordisk outside the submitted work. No other disclosures were reported.

Figures

Figure 1.
Figure 1.. Appendicitis Acuta II Trial Flow Chart
aIncludes appendicolith, perforation, abscess, or suspicion of tumor. bAdditional exclusion criteria were pregnancy, lactation, allergy to contrast media, kidney insufficiency, use of metformin, systemic illness, and inability to consent. cRandomized, placebo-controlled, double-blind, multicenter trial comparing antibiotic therapy with placebo in the treatment of uncomplicated acute appendicitis. dOne patient in the oral antibiotic monotherapy group mistakenly received the treatment intended for the combined intravenous (IV) and oral antibiotics group. ePatients who withdrew consent within 24 hours of randomization who received a maximum of 1 dose of the randomized treatment were excluded. fPatients erroneously randomized despite a finding of complicated acute appendicitis initially seen on computed tomography (CT) imaging were excluded. gOperative or histopathological findings of appendicolith, gangrene, perforation, abscess, or tumor were classified as complicated acute appendicitis. hFollow-up was conducted via telephone interview. If a patient was not reached by telephone, data regarding possible appendectomy was obtained from hospital district electronic medical records.
Figure 2.
Figure 2.. Time to Appendectomy After Initial Treatment of Uncomplicated Acute Appendicitis in Patients in Oral Antibiotics Monotherapy Group vs Combined Intravenous (IV) and Oral Antibiotics Group
The solid dots represent appendectomies of histologically normal appendixes.

Comment on

References

    1. Salminen P, Tuominen R, Paajanen H, et al. . Five-year follow-up of antibiotic therapy for uncomplicated acute appendicitis in the APPAC randomized clinical trial. JAMA. 2018;320(12):1259-1265. doi:10.1001/jama.2018.13201 - DOI - PMC - PubMed
    1. Salminen P, Paajanen H, Rautio T, et al. . Antibiotic therapy vs appendectomy for treatment of uncomplicated acute appendicitis: the APPAC randomized clinical trial. JAMA. 2015;313(23):2340-2348. doi:10.1001/jama.2015.6154 - DOI - PubMed
    1. Davidson GH, Flum DR, Monsell SE, et al. ; CODA Collaborative . Antibiotics versus appendectomy for acute appendicitis: longer-term outcomes. N Engl J Med. 2021;385(25):2395-2397. doi:10.1056/NEJMc2116018 - DOI - PubMed
    1. Ali A, Mobarak Z, Al-Jumaily M, et al. . Cost-utility analysis of antibiotic therapy versus appendicectomy for acute uncomplicated appendicitis. Int J Environ Res Public Health. 2021;18(16):8473. doi:10.3390/ijerph18168473 - DOI - PMC - PubMed
    1. Di Saverio S, Podda M, De Simone B, et al. . Diagnosis and treatment of acute appendicitis: 2020 update of the WSES Jerusalem guidelines. World J Emerg Surg. 2020;15(1):27. doi:10.1186/s13017-020-00306-3 - DOI - PMC - PubMed

MeSH terms

Associated data